# Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome

> **NCT00111956** · PHASE2,PHASE3 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 56 (actual)

## Conditions studied

- Metabolic Syndrome X

## Interventions

- **DRUG:** Etanercept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00111956
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2005-05
- **Final completion:** 2005-05
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2017-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00111956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00111956, "Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00111956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*